GLOBAL-RAYTUR
11.5.2018 04:02:08 CEST | Business Wire | Press release
On May 9th , the mid-term conference of the World Ports Conference was held by International Association of Ports and Harbors (IAPH) in Baku, Azerbaijan. Over 300 ports and port-related companies and organizations worldwide participated in the Conference. As the host for World Ports Conference 2019 and an important foreign trade port of China, Guangzhou Port Authority extended its warm invitation to all guests.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180510006415/en/
To host World Ports Conference 2019 is a milestone for Guangzhou Port. It is also an important step to accelerate the construction and development of national central cities and shipping hubs and the forming of a new pattern of all-around opening up in China. Ms.Yuan stated that “the development of the port cannot be separated from the city. It is even more than just cooperation with the port sector. Instead, the projects should be the trigger activating trades, logistics, ports and other departments to jointly develop and standardize the ports.” She also mentioned that during 31st World Ports Conference in Guangzhou next year the host will launch the ‘Friend Circle’ Initiative for ports along ‘Belt and Road’ to promote trade facilitation and internationalization of Chinese standards.
This time Guangzhou Port Authority chose “Collaborate Now, Create Future” as the theme in its exhibition area, where fully demonstrated the port of Guangzhou as an international shipping hub which is always dedicated to improving modern shipping logistics services and building a smart green and safe port, as well as deepening the exchanges and cooperation internationally. Guangzhou Port Authority also signed a sister port cooperation agreement with Baku International Sea Trade Port, who becomes the 42nd sister port of Guangzhou. Thanks to the conferences of IAPH, Guangzhou Port now maintains friendly cooperation with over 100 countries and 400 ports worldwide.
Since the issuance of the "Three-Year Action Plan for the Construction of the Guangzhou International Shipping Center" in 2015, three years of hard work has led to a big leap in port production, the gathering and radiation power has expanded, new breakthroughs have been made in factor gathering, and key projects such as the Nansha International Cruise Terminal have kicked off. The construction will add new momentum to the gateway hub. China (Guangzhou) International Freight single window has become a leading and demonstrative example among its peers in China.
With the launch of the new 3-year Action Plan, the port of Guangzhou will use the port as a fulcrum to strengthen the connectivity with the regions and cities along the “Belt and Road” initiative, and rapidly enhance the internationalization process of Guangzhou Port. By strictly following the “Belt and Road” initiative and grasping the opportunities of the policy of building a powerful country with strong traffic, powerful oceans, as well as the Bay Area construction of Guangdong, Hong Kong, and Macao, multiple measures will be taken together to promote the construction of the Guangzhou International Shipping Center and jointly create a world-class shipping hub.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180510006415/en/
Contact:
Global Raytur (Beijing) Public Communication Co.,Ltd
Shirley
86
13720002197
wangyishan@globalraytur.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
